Vitrolife AB (publ) acquires eFertility

Rhea-AI Summary

Vitrolife AB (publ) has acquired 100% of the shares in eFertility, a system and software company focused on transforming IVF clinic management. The acquisition is part of Vitrolife Group's strategy to standardize and digitalize IVF clinics globally. eFertility offers innovative solutions like eWitness and eBase, with revenues of EUR 1.5 million in 2023. The purchase price is EUR 9.6 million with a potential earn-out of EUR 8.4 million over three years. The acquisition is expected to close in mid-May 2024, financed by Vitrolife Group's cash.

Positive

• Vitrolife AB (publ) is strategically expanding its presence in the IVF market through the acquisition of eFertility, aiming to bring standardization and digitalization to IVF clinics globally.
• The acquisition includes innovative solutions like eWitness and eBase, which have demonstrated strong demand in the IVF market, positioning Vitrolife Group at the forefront of innovation and automation in IVF clinics worldwide.

Negative

• The earn-out component of EUR 8.4 million based on scale up and sales growth milestones may pose financial risks if not achieved within the stipulated three-year period.

GOTHENBURG, Sweden, May 2, 2024 /PRNewswire/ -- Vitrolife AB (publ) today signed an agreement to acquire 100% of the shares in eFertility (STB Zorg B.V.). This acquisition is a key element of the Vitrolife Group's strategy to bring increased standardisation and digitalisation to IVF clinics around the world.

eFertility is an innovative system and software company transforming IVF clinic management with its cutting-edge solutions: eWitness (witnessing system to track and trace each step of the IVF procedure) and eBase (a specialised EMR that is compatible with hospital information systems). eFertility has a leading presence in the Netherlands and is rapidly expanding across Europe. In 2023, the company had revenues of EUR 1.5 million with a strong sales pipeline demonstrating the increased demand for witnessing systems in the IVF market.  

The initial purchase price, on a net debt free basis is EUR 9.6 million which will be paid at closing. In addition, there is an earn-out component, structured over a 3-year period, based on scale up and achievement of sales growth milestones to a maximum payout of EUR 8.4 million. The expected closing is mid-May 2024 and will be financed through the Vitrolife Group's cash. eFertility will be reported under the Technologies business area. 

The Vitrolife Group is executing on a new five-year corporate strategy, an important element of which is to build an end-to-end platform connecting the products and services across the entire IVF workflow. The eFertility witnessing system and EMR are core elements of that strategy and combined with the rest of the Vitrolife Group portfolio uniquely position the company to be at the forefront of innovation and automation in IVF clinics around the world.   

"The acquisition of eFertility represents a significant step in the Vitrolife Group's strategy to transform and digitalise the IVF patient journey. By incorporating eFertility's technologies into our platform, we are making critical advancements towards the development of a seamlessly integrated and more efficient clinic workflow," said Bronwyn Brophy O'Connor, CEO of Vitrolife Group.

Jan-Willem Broekman, CEO of eFertility, shared, "Joining the Vitrolife Group opens an exciting chapter for eFertility. Together, we will continue to push the boundaries of innovation, delivering integrated solutions that address the evolving needs of IVF clinics worldwide."

Gothenburg, May 2, 2024 
VITROLIFE AB (publ)
Bronwyn (Brophy) O'Connor, CEO

This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 02-05-2024 15:30 CET.

Contact: 
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/vitrolife-ab--publ-/r/vitrolife-ab--publ--acquires-efertility,c3972256

The following files are available for download:

https://mb.cision.com/Main/1031/3972256/2775273.pdf

Vitrolife AB (publ) acquires eFertility

 

View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-publ-acquires-efertility-302134594.html

SOURCE Vitrolife AB (publ)

FAQ

What is the name of the company Vitrolife AB (publ) has acquired?

Vitrolife AB (publ) has acquired eFertility.

What are the innovative solutions offered by eFertility?

eFertility offers eWitness (witnessing system for IVF procedures) and eBase (specialized EMR).

What was eFertility's revenue in 2023?

eFertility had revenues of EUR 1.5 million in 2023.

How will the acquisition be financed?

The acquisition will be financed through Vitrolife Group's cash.

When is the expected closing date of the acquisition?

The acquisition is expected to close in mid-May 2024.